Displaying drugs 7926 - 7950 of 8043 in total
Refametinib
Investigational
Elvucitabine
Investigational
ETC-1001
ETC-1001 is Pfizer’s lead oral small molecule product candidate which is intended to be a chronic treatment for individuals with lipid disorders.
Investigational
TAS-108
Investigational
AEOL-10150
AEOL 10150 is developed by Aeolus as a therapeutic agents based on its proprietary small molecule catalytic antioxidants.
Investigational
Acetylcysteine zidrimer
Investigational
PPI-1019
Apan (PPI-1019) is developed by Praecis Pharmaceuticals to treat Alzheimer's Disease.
Investigational
Siplizumab
Investigational
Quercetin
Quercetin is a flavonol widely distributed in plants. It is an antioxidant, like many other phenolic heterocyclic compounds. Glycosylated forms include RUTIN and quercetrin.
Experimental
Investigational
LY2181308
LY2181308 is investigated in clinical trials for treating solid tumors. LY2181308 is a solid. LY2181308 is directed against a molecular target called survivin. LY2181308 is known to target baculoviral IAP repeat-containing protein 5. LY2181308 is an anti-sense oligonucleotide that potently downregulated survivin expression in human cancer cells derived from lung,...
Investigational
Spermine
Spermine is a spermidine-derived biogenic polyamine found as a polycation at all pH values. Found in various tissues and organisms, it often acts as an essential growth factor in some bacterial species. Spermine is associated with nucleic acids, particularly in viruses, and is thought to stabilize the helical structure.
Experimental
Nutraceutical
Cintredekin besudotox
Cintredekin besudotox has been developed as a specific tumor-targeting agent, which is administered by positive-pressure convection-enhanced delivery (CED) directly to brain tissue at risk for residual infiltrating glioblastoma multiforme (GBM) after tumor resection. Cintredekin besudotox is made from a human protein, Interleukin 13 (IL13), linked to a bacterial toxin, Pseudomonas...
Investigational
Inecalcitol
Investigational
TA-CIN
TA-CIN is a subunit vaccine comprising L2/E6/E7 proteins from Human Papillomavirus (HPV16), designed to generate a strong cellular immune response against HPV-infected cells.
Investigational
XR5944
XR5944 is a DNA bis-intercalating anticancer drug. It has both intercalating and antineoplastic activities.
Investigational
AP1081
A transdermal gel containing ethinyl estradiol and norelgestromin being investigated by Antares Pharma for use as a female contraceptive.
Investigational
Bardoxolone methyl
Investigational
Sufugolix
Investigational
Carotuximab
Investigational
Axatilimab
Axatilimab is under investigation in clinical trial NCT04301778 (Durvalumab in Combination With a CSF-1R Inhibitor (SNDX-6532) Following Chemo or Radio-embolization for Patients With Intrahepatic Cholangiocarcinoma).
Investigational
ACR-16
ACR-16 is under investigation by NeuroSearch. ACR16 has been successfully investigated in a Phase II multi-centre, randomised and placebo-controlled trial in patients with Huntington’s disease as well as in three Phase Ib studies within Huntington’s disease, Parkinson’s disease and schizophrenia respectively. ACR-16 is a dopamine stabilizer. ACR-16 is also being...
Investigational
Taribavirin
Investigational
R-348
Investigational
Interferon Gamma
Interferon gamma is a Type 1 inflammatory cytokine and the only type II interferon. It has antitumor properties, antiviral activities, and important immunoregulatory functions. The interferon is primarily produced by activated T lymphocytes and natural killer cells.
Investigational
EHT 0202
EHT 0202 is developed to treat neurodegenerative disorders by ExonHit Therapeutics.
Investigational
Displaying drugs 7926 - 7950 of 8043 in total